| 19.09 14:21 | dpa-AFX: AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination |
| 18.09 10:24 | dpa-AFX: ANALYSE-FLASH: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15914 Pence |
| 18.09 10:24 | dpa-AFX: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15914 Pence |
| 18.09 08:20 | dpa-AFX: AstraZeneca: Fasenra Approved By FDA To Treat Eosinophilic Granulomatosis With Polyangiitis |
| 18.09 08:02 | dpa-AFX: *ASTRAZENECA'S FASENRA APPROVED IN US FOR TREATMENT OF ADULT PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS |
| 18.09 08:02 | dpa-AFX: *ASTRAZENECA: FDA APPROVES FASENRA IN THE US FOR TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS IN ADULTS |
| 17.09 10:33 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 17.09 10:33 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 16.09 13:48 | dpa-AFX: AstraZeneca Reports 5-year Follow-up Data From HIMALAYA Study In Liver Cancer |
| 16.09 13:05 | dpa-AFX: *AZN : IMFINZI AND IMJUDO SHOW UNPRECEDENTED 5-YEAR SURVIVAL IN ADVANCED LIVER CANCER IN PHASE III TRIAL |
| 16.09 07:28 | dpa-AFX: ANALYSE-FLASH: UBS belässt Astrazeneca auf 'Sell' - Ziel 11300 Pence |
| 16.09 07:28 | dpa-AFX: UBS belässt Astrazeneca auf 'Sell' - Ziel 11300 Pence |
| 15.09 19:09 | dpa-AFX: AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive Bladder Cancer Trial |
| 13.09 18:17 | dpa-AFX: AZN: ENHERTU Phase IIIb/IV Trial Shows Significant Results In HER2-Positive Breast Cancer Patients |
| 13.09 16:28 | dpa-AFX: *AZN : ENHERTU PHASE IIIB/IV TRIAL DELIVERS STRONG RESULTS IN HER2-POSITIVE BREAST CANCER |
| 13.09 11:05 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank Research senkt Astrazeneca auf 'Sell' |
| 13.09 11:05 | ANALYSE-FLASH: Deutsche Bank Research senkt Astrazeneca auf 'Sell' |
| 13.09 09:34 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank Research senkt Astrazeneca auf 'Sell' |
| 13.09 09:34 | dpa-AFX: Deutsche Bank Research senkt Astrazeneca auf 'Sell' |
| 13.09 06:41 | dpa-AFX: *DEUTSCHE BANK RESEARCH CUTS ASTRAZENECA TO 'SELL' (HOLD) - PRICE TARGET 10500(11000)P |
|
|
